Quest Diagnostics (DGX) earnings

QUEST DIAGNOSTICS INC· Health Care

Results to: Sep 2026
Latest analysed call: Sep 2026 (Q3 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Quest Diagnostics earnings: last reported Thu, 22 Oct 2026, for the quarter ended Sep 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	3,097 $ million	+10.0% YoY	Quarterly, as filed	Quarter to Sep 2026	Revenue from operations as filed.
Operating margin	15.5 %	+1.8 pts YoY	Operating profit / revenue	Quarter to Sep 2026	For the quarter; a change is in percentage points.
Net profit	312 $ million	+27.3% YoY	Quarterly, as filed	Quarter to Sep 2026	Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Sep 2026

Guidance

What management said, and what became of it

12 of 20 judged targets kept · 42 open · verdicts reflect calls analysed to Sep 2026.

QUEST DIAGNOSTICS INC management guidance track record on Inve: 62 targets tracked across analysed earnings calls (12 achieved, 8 missed, 42 open).

Target	Original wording	Said	Latest call	Verdict
Adjusted EPS	$10.50 to $10.70	Dec 2025	Sep 2026:adjusted EPS in a range of $11.25 to $11.35. Call transcript, Sep 2026 · no direct link	Revised Up
Acquisition of outreach assets from Northeastern US health system	close transaction	Sep 2026	Sep 2026:We expect to close this transaction later this year. Call transcript, Sep 2026 · no direct link	New

Source: Inve Guidance Tracker for QUEST DIAGNOSTICS INC · to Sep 2026

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

8 of QUEST DIAGNOSTICS INC's 62 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 60 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.

See the full record

Price

$241.89 −0.57% · −$1.39

Last close Oct 23, 2026 · US · USD · Source: Inve

Performance +33.5% 1Y

1Y: $181.17 on 22 Oct 2025 → $241.89. High $247.45 (17 Sept 2026), low $173.49 (5 Jan 2026).

Previous close: $243.28
52-week range: $173.49 – $247.45
One year: +32.01%

Overview

Symbol: DGX
Sector: Health Care
Exchange: US
Currency: USD

Guidance

What management said, and what became of it

12 of 20 judged targets kept · 42 open · verdicts reflect calls analysed to Sep 2026.

QUEST DIAGNOSTICS INC management guidance track record on Inve: 62 targets tracked across analysed earnings calls (12 achieved, 8 missed, 42 open).

Target	Original wording	Said	Latest call	Verdict
Adjusted EPS	$10.50 to $10.70	Dec 2025	Sep 2026:adjusted EPS in a range of $11.25 to $11.35. Call transcript, Sep 2026 · no direct link	Revised Up
Acquisition of outreach assets from Northeastern US health system	close transaction	Sep 2026	Sep 2026:We expect to close this transaction later this year. Call transcript, Sep 2026 · no direct link	New

Source: Inve Guidance Tracker for QUEST DIAGNOSTICS INC · to Sep 2026

The full ledger

Open QUEST DIAGNOSTICS INC’s full ledger

A free account opens 5 company ledgers a month. All 62 tracked commitments, with each call’s wording and source.

Browse the register

Financials

What the filings say

Net profit, year on year: +27% (quarter to sep 2026 against sep 2025).

In $ million. Oldest period first.

Line item	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Sales	2,621	2,652	2,761	2,816	2,806	2,895	3,043	3,097
Expenses	2,260	2,306	2,323	2,430	2,420	2,496	2,584	2,618
Operating profit	361	346	438	386	386	399	459	479
Operating margin	13.8%	13.1%	15.9%	13.7%	13.8%	13.8%	15.1%	15.5%
Other income	-62	-70	-54	-58	-56	-65	-47	-63
Profit before tax	299	276	384	328	330	334	412	416
Tax rate	22.7%	21.4%	25.3%	23.5%	24.6%	22.2%	21.4%	23.8%
Net profit	222	220	282	245	245	252	320	312
EPS ($ per share)	—	1.97	2.51	2.18	—	2.27	2.88	2.82

Source: Inve data · income statement, quarterly · to Sept 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	2	2	2	2	2	2	2	2
Reserves	7,602	8,174	9,303	7,649	8,290	8,825	9,360	9,994
Total liabilities	5,736	7,156	7,217	7,128	6,907	7,680	9,340	9,019
Fixed assets	1,288	1,453	1,627	1,707	1,766	1,816	2,113	2,203
Total assets	11,003	12,843	14,026	13,611	12,837	14,022	16,153	16,225

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	1,200	1,243	2,005	2,233	1,718	1,272	1,334	1,886
Cash from investing	-801	-411	-772	21	-543	-1,061	-2,548	-631
Cash from financing	-401	225	-1,267	-2,540	-1,732	160	1,084	-1,388
Net cash flow	—	—	—	-286	-557	371	-137	-129
Capital expenditure	-383	-400	-418	-403	-404	-408	-425	-527
Free cash flow	817	843	1,587	1,830	1,314	864	909	1,359

Source: Inve data · cash flow · to Dec 2025

DGX revenue by segment

DGX revenue by business segment, share of consolidated revenue by quarter
Segment	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026	YoY growth latest quarter
Diagnostic Information Services Business	98%	98%	98%	98%	98%	98%	98%	98%	+10.2%
All Other Segments	2%	2%	2%	2%	2%	2%	2%	2%	+1.6%

Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.

See how segments are shifting across companies → Segment Shift

DGX operating KPIs by quarter

DGX operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Mar 2026 Q1 FY26	Sep 2026 Q3 FY26	Change vs prior quarter
Patient service centers	2,000 There's many parts of the country where even though we have 2,000 patient service centers to conduct blood draws and urine collections, there's parts of the country where we simply don't have some of the coverage, and that includes areas in the upper Midwest, the Great Plains. Source: earnings call transcript	2,000 The panel also includes biometric measurements such as blood pressure and weight at the same time blood is drawn at one of our 2,000 patient service centers. Source: earnings call transcript	0%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Insider filings

119 filings between Nov 5, 2025 and Sep 1, 2026.

Open market

decisions to buy or sell

Purchases

None

No insider bought shares.

Sales

$37.00M

29 sales by 7 insiders

93% filed under a 10b5-1 plan — scheduled in advance, not decided on the day

Compensation

not trading decisions

33: Award — granted as compensation
8: Option exercise — converted options into shares
32: Tax withheld — shares kept back by the company to cover tax

Also filed: 16 L filings, 1 gift.

Who traded

open market only

Insider	Bought	Sold	Last filing
Davis J. E.	—	$17.08M	Sep 1, 2026
Doherty Catherine T.	—	$6.96M	Mar 5, 2026
PREVOZNIK MICHAEL E	—	$6.65M	Aug 28, 2026
KUPPUSAMY KARTHIK	—	$2.17M	Jun 4, 2026
Plewman Patrick	—	$2.03M	Mar 5, 2026
DELANEY MARK E	—	$1.86M	Jul 28, 2026
Gregg Vicky B	—	$239.7K	Nov 25, 2025

Latest filings (50)

Date	Insider	What	Shares	Value
Sep 1, 2026	Davis J. E. CEO and President	Sale 10b5-1 plan	10,000	$2.43M
Aug 28, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Option exercise 10b5-1 plan	22,677	$2.54M
Aug 28, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Sale 10b5-1 plan	16,010	$3.89M
Aug 28, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Sale 10b5-1 plan	6,237	$1.52M
Aug 28, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Gift 10b5-1 plan	1,000	$0
Aug 28, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Sale 10b5-1 plan	430	$105.1K
Jul 28, 2026	DELANEY MARK E SVP & Chief Commercial Officer	Sale 10b5-1 plan	1,600	$376.3K
Jul 22, 2026	Gregg Vicky B Director	Award	72	$14.9K
Jul 22, 2026	DELANEY MARK E SVP & Chief Commercial Officer	Code L	34	$7.0K
Jul 22, 2026	CARTER ROBERT B Director	Code L	11	$2.3K
Jul 22, 2026	Plewman Patrick SVP for Diagnostic Services	Code L	46	$9.5K
Jul 22, 2026	Lassiter Wright III Director	Code L	6	$1.2K
Jul 22, 2026	KUPPUSAMY KARTHIK SVP, Clinical Solutions	Code L	37	$7.7K
Jul 22, 2026	MAIN TIMOTHY L Director	Code L	21	$4.3K
Jul 22, 2026	SAMAD SAM Executive Vice President & CFO	Award	102	$21.1K
Jun 4, 2026	KUPPUSAMY KARTHIK SVP, Clinical Solutions	Option exercise 10b5-1 plan	3,320	$424.0K
Jun 4, 2026	KUPPUSAMY KARTHIK SVP, Clinical Solutions	Sale 10b5-1 plan	8,147	$1.63M
Jun 4, 2026	KUPPUSAMY KARTHIK SVP, Clinical Solutions	Option exercise 10b5-1 plan	4,827	$588.0K
Jun 1, 2026	Davis J. E. CEO and President	Sale 10b5-1 plan	10,000	$1.94M
May 20, 2026	PFEIFFER GARY M Director	Award	1,142	$0
May 20, 2026	Lassiter Wright III Director	Award	1,142	$0
May 20, 2026	Diaz Luis Director	Award	1,142	$0
May 20, 2026	MAIN TIMOTHY L Director	Award	1,142	$0
May 20, 2026	Doi Tracey Director	Award	1,142	$0
May 20, 2026	Gregg Vicky B Director	Award	1,142	$0
May 20, 2026	WENTWORTH TIMOTHY C Director	Award	1,142	$0
May 20, 2026	MORRISON DENISE M Director	Award	1,142	$0
May 20, 2026	CARTER ROBERT B Director	Award	1,142	$0
May 20, 2026	RING TIMOTHY M Director	Award	1,142	$0
Apr 20, 2026	SAMAD SAM Executive Vice President & CFO	Award	108	$21.0K
Apr 20, 2026	Gregg Vicky B Director	Award	68	$13.2K
Apr 20, 2026	Plewman Patrick SVP for Diagnostic Services	Code L	49	$9.5K
Apr 20, 2026	KUPPUSAMY KARTHIK SVP, Clinical Solutions	Code L	39	$7.6K
Apr 20, 2026	CARTER ROBERT B Director	Code L	7	$1.4K
Apr 20, 2026	DELANEY MARK E SVP & Chief Commercial Officer	Code L	37	$7.2K
Apr 20, 2026	Lassiter Wright III Director	Code L	6	$1.2K
Mar 9, 2026	WENTWORTH TIMOTHY C Director	Award	215	$0
Mar 5, 2026	Doherty Catherine T. EVP, Regional Businesses	Sale 10b5-1 plan	5,558	$1.15M
Mar 5, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Sale 10b5-1 plan	3,878	$799.7K
Mar 5, 2026	Plewman Patrick SVP for Diagnostic Services	Sale 10b5-1 plan	2,855	$588.7K
Mar 4, 2026	SAMAD SAM Executive Vice President & CFO	Tax withheld	7,720	$1.58M
Mar 4, 2026	SAMAD SAM Executive Vice President & CFO	Award	13,947	$2.86M
Mar 4, 2026	Doherty Catherine T. EVP, Regional Businesses	Tax withheld 10b5-1 plan	5,806	$1.19M
Mar 4, 2026	Doherty Catherine T. EVP, Regional Businesses	Award 10b5-1 plan	11,364	$2.33M
Mar 4, 2026	DELANEY MARK E SVP & Chief Commercial Officer	Tax withheld	2,326	$476.5K
Mar 4, 2026	DELANEY MARK E SVP & Chief Commercial Officer	Award	5,682	$1.16M
Mar 4, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Tax withheld 10b5-1 plan	3,354	$687.1K
Mar 4, 2026	PREVOZNIK MICHAEL E SVP & General Counsel	Award 10b5-1 plan	7,232	$1.48M
Mar 4, 2026	Davis J. E. CEO and President	Tax withheld	26,414	$5.41M
Mar 4, 2026	Davis J. E. CEO and President	Award	51,652	$10.58M

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for QUEST DIAGNOSTICS INC

Free account. Everything above stays public.

Write why you follow QUEST DIAGNOSTICS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading